Functional Recovery after the Application of Amniotic Tissues and Methylene Blue during Radical Prostatectomy-A Pilot Study. (2023)

Peer-Reviewed Study · Barski D, Tsaur I, Boros M, Brune J, Otto T · August 13, 2023

Barski D et al., 2023-08-13: Retrospective proof-of-concept series of 14 men in which amniotic tissue plus intraoperative methylene blue neurostaining were used during radical prostatectomy; early continence recovery at 3 months, no effect on potency, median follow-up 13 months.

Amniotic tissues and methylene blue (MB) provide the ability for neuroregeneration, and MB enables intraoperative neurostaining. We first combined the techniques to explore a neuroprotective effect on early functional outcomes in a retrospective proof-of-concept trial of 14 patients undergoing radical prostatectomy (RP).

Barski D et al., 2023-08-13: Retrospective proof-of-concept series of 14 men in which amniotic tissue plus intraoperative methylene blue neurostaining were used during radical prostatectomy; early continence recovery at 3 months, no effect on potency, median follow-up 13 months. C4. Study type: retrospective proof-of-concept case series (pilot). N: 14. Country: Germany (Rheinland Klinikum Neuss; University Medical Center Johannes Gutenberg). Methylene blue dose/concentration/route: not stated in the abstract; used intraoperatively to stain the neurovascular bundle. Funder: none declared. Conflicts: 'The authors declare no conflict of interest.' Comparator: none – the authors call for prospective comparative studies. Partly because the functional claim rests on an uncontrolled series and no potency benefit was found. Study type: uncontrolled series.